Advances in cancer immunotherapy have led to clinical trials of immunotherapy-based neoadjuvant treatments for early stage non-small-cell lung cancer. Evidence for priming of the immune system using both preoperative short-course radiotherapy and immunotherapy in this setting has now emerged from a randomized phase II study incorporating pathological and immunological end points.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol. 26, 3552–3559 (2008).
Spigel, D. R. et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial. J. Clin. Oncol. 39 (suppl. 15), 8511 (2021).
Spicer, J. et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J. Clin. Oncol. 39 (suppl. 15), 8503 (2021).
Demaria, S., Coleman, C. N. & Formenti, S. C. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2, 286–294 (2017).
O’Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U. & Teng, M. W. L. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin. Cancer Res. 25, 5743–5751 (2019).
Altorki, N. K. et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 22, 824–835 (2021).
Theelen, W. S. M. E. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276–1282 (2019).
Palma, D. A. et al. Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial. JAMA Oncol. 5, 681–688 (2019).
Krall, J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci. Transl Med. 10, eaan3464 (2018).
Wei, J. et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci. Immunol. 6, eabg0117 (2021).
Acknowledgements
The authors acknowledge the critical review of this commentary by C. Dickhoff, thoracic surgeon, and I. Bahce, pulmonary oncologist, at Amsterdam University Medical Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.S. reports institutional grants and personal fees from AstraZeneca and Varian Medical Systems, institutional grants from Bristol Myers Squibb and ViewRay, and personal fees from BeiGene and MSD. S.S. is a member of the scientific steering committee of the European Thoracic Oncology Group. F.L.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Schneiders, F.L., Senan, S. Finding the Goldilocks zone in neoadjuvant radioimmunotherapy. Nat Rev Clin Oncol 18, 545–546 (2021). https://doi.org/10.1038/s41571-021-00540-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00540-x
